Repository logo
 
Publication

Randomized Clinical Trial of Balloon Occlusion versus Conventional Microcatheter Prostatic Artery Embolization for Benign Prostatic Hyperplasia

2019-11Journal article Open access
Simple item page
dc.contributor.authorBilhim, T
dc.contributor.authorCosta, NV
dc.contributor.authorTorres, D
dc.contributor.authorPisco, J
dc.contributor.authorCarmo, S
dc.contributor.authorOliveira, A
dc.date.accessioned2021-05-06T14:20:30Z
dc.date.available2021-05-06T14:20:30Z
dc.date.issued2019-11
dc.description.abstractPurpose: To compare balloon occlusion prostatic artery embolization (bPAE) with conventional microcatheter PAE (cPAE). Materials and methods: In this single-center trial, between November 2017 and November 2018, 89 patients with symptomatic benign prostatic hyperplasia were randomly assigned to cPAE (n = 43) or bPAE (n = 46). All patients received embolization with 300-500 μm Embosphere microspheres and were evaluated before and 1 and 6 months after PAE. Primary outcome measure was change from baseline in International Prostate Symptom Score (IPSS). Student t test was used for between-group comparisons of change from baseline, and paired t test was used for within-group comparisons. Results: At baseline, groups were identical (P > .05). Unilateral PAE was performed in 4 patients receiving cPAE and 3 patients receiving bPAE (9.30% and 6.52%, P = .708). Procedural and fluoroscopy times, dose area product, air kerma, embolic volume, and mean prostate-specific antigen (PSA) 24 hours after PAE did not differ between groups (P > .05). Coils were used in 6 patients receiving cPAE and 4 patients receiving bPAE (14.0% and 8.70%, P = .51). Assessments at 6 months after PAE showed mean IPSS reduction was 7.58 ± 6.88 after cPAE and 8.30 ± 8.12 after bPAE (P = .65); mean prostate volume reduction was 21.9 cm3 ± 51.6 (18.2%) after cPAE and 6.15 cm3 ± 14.6 (7.3%) after bPAE (P = .05); mean PSA reduction was 0.9 ng/mL ± 2.22 after cPAE and 0.22 ng/mL ± 1.65 after bPAE (P = .10). Penile skin lesions (n = 3) and rectal bleeding (n = 2) were documented only in patients receiving cPAE (11.9%, P = .01). No major adverse events occurred. Conclusions: bPAE is as effective as cPAE in treating benign prostatic hyperplasia with a potential to reduce nontarget embolization.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationJ Vasc Interv Radiol. 2019 Nov;30(11):1798-1806.pt_PT
dc.identifier.doi10.1016/j.jvir.2019.06.019pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.17/3685
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherElsevierpt_PT
dc.subjectAcrylic Resinspt_PT
dc.subjectAgedpt_PT
dc.subjectEmbolization, Therapeuticpt_PT
dc.subjectEquipment Designpt_PT
dc.subjectGelatinpt_PT
dc.subjectHumanspt_PT
dc.subjectMalept_PT
dc.subjectMiddle Agedpt_PT
dc.subjectMiniaturizationpt_PT
dc.subjectPortugalpt_PT
dc.subjectProspective Studiespt_PT
dc.subjectProstatept_PT
dc.subjectProstatic Hyperplasiapt_PT
dc.subjectRadiography, Interventionalpt_PT
dc.subjectRegional Blood Flowpt_PT
dc.subjectSingle-Blind Methodpt_PT
dc.subjectTime Factorspt_PT
dc.subjectTreatment Outcomept_PT
dc.subjectArteriespt_PT
dc.subjectBalloon Occlusionpt_PT
dc.subjectCatheterspt_PT
dc.subjectCHLC IMApt_PT
dc.titleRandomized Clinical Trial of Balloon Occlusion versus Conventional Microcatheter Prostatic Artery Embolization for Benign Prostatic Hyperplasiapt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage1806pt_PT
oaire.citation.issue11pt_PT
oaire.citation.startPage1798pt_PT
oaire.citation.titleJournal of Vascular and Interventional Radiology : JVIRpt_PT
oaire.citation.volume30pt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
JVIR 2019 1798.pdf
Size:
1.59 MB
Format:
Adobe Portable Document Format
Download

Collections

IMA - Artigos